ATE288415T1 - Dinatrium-salze, monohydrate und ethanol-solvate - Google Patents

Dinatrium-salze, monohydrate und ethanol-solvate

Info

Publication number: ATE288415T1
Authority: AT; Austria
Prior art keywords: ethanol; delivery agents; disodium salt; monohydrates; hydroxybenzoyl
Prior art date: 1999-04-05

Application number

AT00921909T

Other languages

English (en)

Inventor

William E Bay

Rajesh K Agarwal

Kiran Chaudhary

Shingai Majuru

Michael M Goldberg

Joanne P Russo

Original Assignee

Emisphere Tech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-04-05

Filing date

2000-04-05

Publication date

2005-02-15

2000-04-05 Application filed by Emisphere Tech Inc filed Critical Emisphere Tech Inc

2005-02-15 Application granted granted Critical

2005-02-15 Publication of ATE288415T1 publication Critical patent/ATE288415T1/de

Links

LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title abstract 8
239000012453 solvate Substances 0.000 title abstract 4
150000004682 monohydrates Chemical class 0.000 title 1
159000000000 sodium salts Chemical class 0.000 title 1
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 abstract 4
229940124447 delivery agent Drugs 0.000 abstract 3
125000003816 2-hydroxybenzoyl group Chemical group OC1=C(C(=O)*)C=CC=C1 0.000 abstract 2
XRTHAPZDZPADIL-UHFFFAOYSA-N 8-[(5-chloro-2-hydroxybenzoyl)amino]octanoic acid Chemical compound OC(=O)CCCCCCCNC(=O)C1=CC(Cl)=CC=C1O XRTHAPZDZPADIL-UHFFFAOYSA-N 0.000 abstract 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 abstract 1
GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 abstract 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 abstract 1
239000013543 active substance Substances 0.000 abstract 1
150000004677 hydrates Chemical class 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 abstract 1
229910052708 sodium Inorganic materials 0.000 abstract 1
239000011734 sodium Substances 0.000 abstract 1
XUHVCHNJCBBXMP-UHFFFAOYSA-M sodium;10-[(2-hydroxybenzoyl)amino]decanoate Chemical compound [Na+].OC1=CC=CC=C1C(=O)NCCCCCCCCCC([O-])=O XUHVCHNJCBBXMP-UHFFFAOYSA-M 0.000 abstract 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/24—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in positions 2 and 4
- C07D265/26—Two oxygen atoms, e.g. isatoic anhydride
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Hematology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oil, Petroleum & Natural Gas (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Obesity (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

AT00921909T 1999-04-05 2000-04-05 Dinatrium-salze, monohydrate und ethanol-solvate ATE288415T1 (de)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US12775499P	1999-04-05	1999-04-05
US18614300P	2000-03-01	2000-03-01
US18614200P	2000-03-01	2000-03-01
US19128600P	2000-03-21	2000-03-21
PCT/US2000/009390 WO2000059863A1 (en)	1999-04-05	2000-04-05	Disodium salts, monohydrates, and ethanol solvates

Publications (1)

Publication Number	Publication Date
ATE288415T1 true ATE288415T1 (de)	2005-02-15

Family

ID=27494697

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00921909T ATE288415T1 (de)	1999-04-05	2000-04-05	Dinatrium-salze, monohydrate und ethanol-solvate

Country Status (11)

Country	Link
US (6)	US20020065255A1 (de)
EP (1)	EP1175390B1 (de)
JP (2)	JP4588221B2 (de)
AT (1)	ATE288415T1 (de)
AU (1)	AU4216700A (de)
CA (1)	CA2369591C (de)
DE (1)	DE60017888T2 (de)
ES (1)	ES2235854T3 (de)
IL (4)	IL145546A0 (de)
NZ (1)	NZ534409A (de)
WO (1)	WO2000059863A1 (de)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6461643B2 (en)	1993-04-22	2002-10-08	Emisphere Technologies, Inc.	Oral drug delivery compositions and methods
IL126318A (en)	1996-03-29	2004-09-27	Emisphere Tech Inc	Compounds and compositions for delivering active agents and some novel carrier compounds
US6358504B1 (en)	1997-02-07	2002-03-19	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US6440929B1 (en)	1998-07-27	2002-08-27	Emisphere Technologies, Inc.	Pulmonary delivery of active agents
JP5144861B2 (ja)	1998-07-27	2013-02-13	エミスフェアー・テクノロジーズ・インク	活性剤のデリバリーのための化合物及び組成物
US6991798B1 (en)	1998-08-07	2006-01-31	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
IL140930A0 (en)	1998-08-07	2002-02-10	Emisphere Tech Inc	Compounds and compositions for delivering active agents
ES2235854T3 (es) *	1999-04-05	2005-07-16	Emisphere Technologies, Inc.	Sales disodicas, monohidratos y solvatos etanolicos para aportar agentes activos.
US7129274B1 (en)	1999-11-05	2006-10-31	Emisphere Technologies Inc.	Phenoxy carboxylic acid compounds and compositions for delivering active agents
US7279597B1 (en)	1999-11-05	2007-10-09	Emisphere Technologies, Inc.	Phenyl amine carboxylic acid compounds and compositions for delivering active agents
US7151191B2 (en)	2000-01-13	2006-12-19	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
ES2306719T3 (es)	2000-06-29	2008-11-16	Emisphere Technologies, Inc.	Compuestos y composiciones para la administracion de principios activos.
US7049283B2 (en)	2000-12-06	2006-05-23	Novartis Ag	Pharmaceutical compositions for the oral delivery of pharmacologically active agents
JP5073153B2 (ja) *	2001-06-01	2012-11-14	ノバルティスアーゲー	副甲状腺ホルモンおよびカルシトニンの経口投与
KR20040030120A (ko) *	2001-08-17	2004-04-08	노파르티스 아게	부갑상선 호르몬 단편의 경구 전달제로서의 5-ｃｎａｃ
CA2466863A1 (en) *	2001-11-29	2003-06-05	Emisphere Technologies, Inc.	Oral pharmaceutical compositions comprising cromolyn sodium and an acylated amino acid
EP1469827B1 (de) *	2002-01-09	2017-12-27	Emisphere Technologies, Inc.	Polymorphe von natrium-4-(4-chlor-2-hydroxybenzoyl)aminobutanoat
PL209734B1 (pl)	2002-02-20	2011-10-31	Emisphere Tech Inc	Preparat farmaceutyczny zawierający związek GLP-1 i czynnik dostarczający oraz jego zastosowanie
US20050054557A1 (en) *	2002-05-09	2005-03-10	Goldberg Michael M.	Compositions for delivering parathyroid hormone and calcitonin
TW200403052A (en) *	2002-07-17	2004-03-01	Novartis Ag	Use of organic compounds
TWI307279B (en) *	2002-08-01	2009-03-11	Novartis Ag	Oral administration of calcitonin
US20070065505A1 (en)	2003-07-11	2007-03-22	Shoufeng Li	Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form
ES2398237T3 (es)	2003-07-23	2013-03-14	Novartis Ag	Uso de calcitonina en osteoartritis
US7318925B2 (en) *	2003-08-08	2008-01-15	Amgen Fremont, Inc.	Methods of use for antibodies against parathyroid hormone
CN1838968A (zh)	2003-08-08	2006-09-27	艾伯吉尼斯公司	针对甲状旁腺激素(pth)之抗体和其用途
EP1658285B1 (de)	2003-08-20	2007-05-02	Eli Lilly And Company	Verbindungen, verfahren und formulierungen zur oralen verabreichung einer glucagonartigen peptid (glp)-1-verbindung oder eines melanocortin-4-rezeptor-(mc4-)agonistschen peptids
ATE350369T1 (de)	2003-08-20	2007-01-15	Lilly Co Eli	Verbindungen, verfahren und formulierungen zur oralen verabreichung einer glucagon like peptide (glp)-1-verbindung oder eines am melanocortin-4- rezeptor (mc4) als agonist wirkenden peptids
US20060286129A1 (en)	2003-12-19	2006-12-21	Emisphere Technologies, Inc.	Oral GLP-1 formulations
KR20060134216A (ko)	2004-04-16	2006-12-27	에미스페어 테크놀로지스, 인코포레이티드	활성제 전달을 위한 8-(2-히드록시페녹시)옥틸디에탄올아민및 그의 염
KR101193228B1 (ko) *	2004-05-06	2012-10-22	에미스페어 테크놀로지스, 인코포레이티드	모노소듐 ｎ-［8-(2-히드록시벤조일)아미노］카프릴레이트의 결정 다형 형태
CN102040535B (zh)	2004-05-06	2012-10-17	爱密斯菲尔科技公司	N-[8-(2-羟基苯甲酰基)氨基]辛酸一钠的晶体的多晶
CN1953753B (zh) *	2004-05-06	2011-02-09	爱密斯菲尔科技公司	N-[8-(2-羟基苯甲酰基)氨基]辛酸一钠的晶体的多晶
JP2007536268A (ja)	2004-05-06	2007-12-13	エミスフェアー・テクノロジーズ・インク	固体剤形の湿性ヘパリン
RU2403237C2 (ru) *	2004-05-14	2010-11-10	Эмисфире Текнолоджис, Инк.	Составы и смеси для доставки активных агентов
MXPA06013252A (es)	2004-05-14	2007-02-28	Emisphere Tech Inc	Compuestos y composiciones para suministrar agentes activos.
NZ551241A (en)	2004-05-14	2010-08-27	Emisphere Tech Inc	Aryl ketone compounds and compositions for delivering active agents
CN1968704B (zh) *	2004-05-19	2010-12-08	爱密斯菲尔科技公司	局部用色甘酸制剂
BRPI0510820A (pt) *	2004-05-19	2007-11-27	Emisphere Tech Inc	composição farmacêutica, forma unitária de dosagem e seus usos
MX2007000510A (es) *	2004-07-12	2007-03-29	Emisphere Tech Inc	Composiciones para suministrar peptido yy y agonistas de pyy.
EP1773376A4 (de)	2004-08-03	2009-07-01	Emisphere Tech Inc	Antidiabetische orale insulinbiguanidkombination
GB0422644D0 (en) *	2004-10-12	2004-11-10	Novartis Ag	Organic compounds
GB0427600D0 (en) *	2004-12-16	2005-01-19	Novartis Ag	Organic compounds
GB0427603D0 (en)	2004-12-16	2005-01-19	Novartis Ag	Organic compounds
AU2005321803B2 (en)	2004-12-29	2012-02-09	Emisphere Technologies, Inc.	Pharmaceutical formulations of gallium salts
US8110547B2 (en)	2005-01-12	2012-02-07	Emisphere Technologies, Inc.	Compositions for buccal delivery of parathyroid hormone
WO2007005995A2 (en) *	2005-07-05	2007-01-11	Emisphere Technologies, Inc.	Compositions for buccal delivery of human growth hormone
US20070049557A1 (en)	2005-08-24	2007-03-01	Hashim Ahmed	Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
CN105641686A (zh) *	2005-09-19	2016-06-08	爱密斯菲尔科技公司	N-(5-氯水杨酰基)-8-氨基辛酸的二钠盐的晶形
GB0522566D0 (en) *	2005-11-04	2005-12-14	Novartis Ag	Organic compounds
AU2006318815B2 (en)	2005-11-17	2010-08-19	Novartis Ag	Pharmaceutical composition
US20070232537A1 (en) *	2005-12-19	2007-10-04	Nastech Pharmaceutical Company Inc.	Intranasal pyy formulations with improved transmucosal pharmacokinetics
WO2007121318A2 (en)	2006-04-12	2007-10-25	Emisphere Technologies, Inc.	Formulations for delivering insulin
US8771712B2 (en)	2006-05-09	2014-07-08	Emisphere Technologies, Inc.	Topical administration of acyclovir
JP5475443B2 (ja) *	2006-06-28	2014-04-16	エミスフェアー・テクノロジーズ・インク	硝酸ガリウム製剤
AU2007284801A1 (en)	2006-08-08	2008-02-21	The Regents Of The University Of Californina	Salicylanilides enhance oral delivery of therapeutic peptides
BRPI0716261A2 (pt)	2006-08-31	2013-08-06	Novartis Ag	composiÇÕes farmacÊuticas compreendendo hch para distribuiÇço oral
JP5577094B2 (ja) *	2006-08-31	2014-08-20	エミスフェアー・テクノロジーズ・インク	活性薬剤を送達するための化合物及び組成物
BRPI0716539A2 (pt) *	2006-09-07	2016-11-01	Emisphere Tech Inc	métodos para sintetização de ácido n-(8-[2-hidroxibenzoil]amino) caprílico e de sal de sódio deste
CN101621991A (zh)	2007-03-02	2010-01-06	诺瓦提斯公司	降钙素的口服施用
EP3050568B1 (de)	2007-03-13	2020-12-02	JDS Therapeutics, LLC	Verfahren und zusammensetzungen zur verzögerten freisetzung von chrom
WO2009002867A2 (en)	2007-06-26	2008-12-31	Nutrition 21, Inc.	Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
EP2460515B1 (de)	2007-08-09	2017-03-08	Novartis AG	Orale Calcitonin-Zusammensetzungen und ihre Anwendungen
PL2215047T3 (pl) *	2007-11-02	2014-05-30	Emisphere Tech Inc	Sposób leczenia niedoborów witaminy b12
ES2439767T3 (es) *	2008-08-01	2014-01-24	Purdue Pharma Lp	Compuestos de tetrahidropiridinilo y dihidropirrolilo y uso de los mismos
AU2010210600B2 (en)	2009-02-06	2016-07-14	C3 Jian, Inc.	Calcium-binding agents induce hair growth and/or nail growth
CA2755068C (en)	2009-03-12	2018-11-06	Keybioscience Ag	Treatment of diabetes and metabolic syndrome
US20110039930A1 (en)	2009-08-03	2011-02-17	Emisphere Technologies, Inc.	Fast-acting naproxen composition with reduced gastrointestinal effects
WO2011106378A2 (en) *	2010-02-24	2011-09-01	Emisphere Technologies, Inc.	Oral b12 therapy
EP2579868B1 (de) *	2010-06-09	2018-03-07	Emisphere Technologies, Inc.	Orale therapie gegen eisenmangel
ES2705027T3 (es)	2010-08-19	2019-03-21	Buck Institute For Age Res	Métodos de tratamiento del deterioro cognitivo leve (DCL) y trastornos relacionados
ES2678145T3 (es)	2010-08-24	2018-08-09	Abbott Laboratories	Anticuerpos específicos contra la proteína del núcleo del VIH y usos de los mismos
US8709310B2 (en) *	2011-01-05	2014-04-29	Hospira, Inc.	Spray drying vancomycin
EP4070801A1 (de)	2011-03-01	2022-10-12	Nutrition 21, LLC	Zusammensetzungen aus insulin und chrom zur behandlung und vorbeugung von diabetes, hypoglykämie und verwandten erkrankungen
EP3357540A1 (de)	2011-11-02	2018-08-08	KeyBioscience AG	Zusammensetzung aus einen calcitoninmimetika und einen nsulin-sensibilisator
US9533022B2 (en) *	2011-11-02	2017-01-03	KeyBioscience A/S	Peptide analogs for treating diseases and disorders
US9006172B2 (en)	2011-11-02	2015-04-14	Keybioscience Ag	Peptide analogs for treating diseases and disorders
CA2881479A1 (en)	2012-08-16	2014-02-20	Ohio State Innovation Foundation	Stat3 inhibitors and their anticancer use
EP2890370B1 (de)	2012-08-31	2019-10-09	The Regents of the University of California	Mittel zur behandlung von adipositas, diabetes und verwandten erkrankungen
PL2897620T3 (pl)	2012-09-21	2020-11-02	Intensity Therapeutics, Inc	Sposób leczenia nowotworu złośliwego
AU2013352141B2 (en)	2012-11-30	2018-04-05	The Regents Of The University Of California	Anticonvulsant activity of steroids
CN104043104B (zh)	2013-03-15	2018-07-10	浙江创新生物有限公司	含盐酸万古霉素的喷雾干粉及其工业化制备方法
AU2014287044B2 (en) *	2013-07-12	2020-02-06	Genentech, Inc.	Elucidation of ion exchange chromatography input optimization
CN105722854B (zh)	2013-11-14	2020-08-04	关键生物科学有限公司	用于治疗疾病和病症的降钙素模拟物
ES2630106T3 (es)	2014-10-07	2017-08-18	Cyprumed Gmbh	Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos
CA3000633C (en)	2014-10-14	2023-10-03	The Regents Of The University Of California	Use of cdk9 and brd4 inhibitors to inhibit inflammation
GB201500263D0 (en)	2015-01-08	2015-02-25	Keybioscience Ag	Calcitonin analogues for treating diseases and disorders
US20180036382A1 (en)	2015-02-09	2018-02-08	Entera Bio Ltd.	Formulations for oral administration of active agents with controlled absorption profile
JP2018529749A (ja)	2015-10-07	2018-10-11	シプルメット・ゲーエムベーハー	ペプチド薬物を経口送達するための医薬製剤
CA3014308A1 (en)	2016-02-11	2017-08-17	Nutrition 21, Llc	Chromium containing compositions for improving health and fitness
BR112018071518A2 (pt)	2016-04-22	2019-02-19	Receptor Life Sciences, Inc.	compostos medicinais à base de planta de ação rápida e suplementos nutricionais
CN116850132A (zh)	2016-08-17	2023-10-10	安提拉生物有限公司	用于口服的活性剂的制剂
WO2018065634A1 (en)	2016-10-07	2018-04-12	Cyprumed Gmbh	Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
EA201892396A1 (ru)	2016-12-02	2019-04-30	Ресептор Лайф Сайенсиз, Инк.	Быстродействующие растительные лекарственные соединения и биологически активные добавки
EP3565573B1 (de)	2017-01-05	2023-08-23	The Regents of The University of California	Pac1-rezeptor-agonisten (maxcaps) und verwendungen davon
GB201704429D0 (en)	2017-03-21	2017-05-03	Keybioscience Ag	Calcitonin mimetics for treating diseases and disorders
GB201707955D0 (en)	2017-05-18	2017-07-05	Keybioscience Ag	Dual amylin and calcitonin receptor agonists for treating diseases and disorders
CA3078549A1 (en) *	2017-10-05	2019-04-11	Receptor Holdings, Inc.	Rapid onset and extended action plant-based and synthetic cannabinoid formulations
JP2020536858A (ja) *	2017-10-05	2020-12-17	レセプター・ホールディングス・インコーポレイテッド	改善されたバイオアベイラビリティーを有するハーブ組成物
WO2019083904A1 (en)	2017-10-23	2019-05-02	Chan Zuckerberg Biohub, Inc.	AFUCOSYLATED IGG FC GLYCANES MEASUREMENT AND METHODS OF TREATMENT THEREOF
WO2019193204A1 (en)	2018-04-06	2019-10-10	Cyprumed Gmbh	Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
GB201813677D0 (en)	2018-08-22	2018-10-03	Keybioscience Ag	Calcitonin mimetics for treating diseases and disorders
GB201813678D0 (en)	2018-08-22	2018-10-03	Keybioscience Ag	Acylated calcitonin mimetics
EP3883595A4 (de)	2018-11-19	2022-12-14	Receptor Holdings, Inc.	N-acylierte fettaminosäuren zur verminderung der absorptionsvariabilität bei zusammensetzungen auf cannabinoid-basis
CN111057165A (zh) *	2020-01-13	2020-04-24	苏州健飞肠衣有限公司	一种高纯度肝素钠的制备方法
EP4210680A1 (de)	2020-09-07	2023-07-19	Cyprumed GmbH	Verbesserte pharmazeutische formulierungen von glp-1-rezeptoragonisten
CR20230308A (es)	2020-12-11	2023-09-08	Civi Biopharma Inc	Entrega oral de conjugados antisentido que tienen por blanco a pcsk9
JP2024505911A (ja)	2021-01-29	2024-02-08	ノボ・ノルデイスク・エー／エス	アミド形成によるサルカプロジン酸の新規合成
ES3064753T3 (en)	2021-04-16	2026-04-28	Navinta Iii Inc	Process for the preparation of highly pure salcaprozic acid and pharmaceutically acceptable salts thereof
US11667614B2 (en)	2021-04-16	2023-06-06	Navinta III Inc.	Process for the preparation of highly pure Salcaprozic Acid and pharmaceutically acceptable salts thereof
CR20230471A (es)	2021-04-22	2023-11-01	Civi Biopharma Inc	Administración oral de oligonucleótidos
CA3223247A1 (en)	2021-07-16	2023-01-19	Thomas Kvistgaard Vilhelmsen	Sodium n-(8-(2- hydroxybenzoyl)amino)caprylate polymorphic form a
JP2025508982A (ja)	2022-03-03	2025-04-10	サイプルメドゲーエムベーハー	治療用ペプチドおよびタンパク質の改善された経口医薬製剤
JP2026502943A (ja)	2022-12-30	2026-01-27	アルギファルマエーエス	経口投与されるポリペプチド治療剤の全身バイオアベイラビリティを高める組成物および方法
WO2024211393A2 (en)	2023-04-04	2024-10-10	Tulex Pharmaceuticals Inc.	Desmopressin oral compositions

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES369853A1 (es) *	1969-07-24	1971-07-16	Bama S A Lab	Procedimiento para la obtencion de derivados del acido ep- silon-amino-caproico.
US3795739A (en) *	1972-02-14	1974-03-05	Hoffmann La Roche	Treatment of parkinson disease
US3939253A (en) *	1973-11-02	1976-02-17	Interx Research Corporation	Novel, transient pro-drug forms of l-dopa useful in the treatment of parkinson's disease
US4061466A (en) *	1974-10-16	1977-12-06	Ingvar Gosta Holger Sjoholm	Biologically active composition and the use thereof
DE2500157C2 (de) *	1975-01-03	1983-09-15	Hoechst Ag, 6230 Frankfurt	N-Acyl-4-(2-aminoäthyl)-benzoesäuren, deren Salze und Ester, Verfahren zu deren Herstellung und deren Verwendung
US4035507A (en) *	1975-04-17	1977-07-12	Interx Research Corporation	Novel, transient pro-drug forms of L-DOPA to treat Parkinson's disease
DE2517229A1 (de) *	1975-04-18	1976-10-28	Boehringer Mannheim Gmbh	Phenylalkylcarbonsaeure-derivate und verfahren zu ihrer herstellung
DE2532420A1 (de) *	1975-07-19	1977-02-03	Boehringer Mannheim Gmbh	Phenylessigsaeure-derivate und verfahren zu ihrer herstellung
CA1077842A (en) *	1975-10-09	1980-05-20	Minnesota Mining And Manufacturing Company	Albumin medicament carrier system
FR2374910A1 (fr) *	1976-10-23	1978-07-21	Choay Sa	Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations
NZ196349A (en)	1980-03-07	1984-08-24	Interx Research Corp	Enhancement of absorption rate of orally administered polar bioactive agents
US4442090A (en) *	1980-11-09	1984-04-10	Kyoto Yakuhin Kogyo Kabushiki Kaisha	Absorption-promoting compounds, compositions thereof with pharmaceuticals and/or bases for rectal administration and method of use
US4900730A (en) *	1981-01-14	1990-02-13	Toyo Jozo Co., Ltd.	Preparation which promotes the absorption of peptides
GB2092136B (en) *	1981-01-17	1985-06-05	Mitsui Toatsu Chemicals	Production of n-substituted amide compounds
JPS58140026A (ja) *	1982-01-14	1983-08-19	Toyo Jozo Co Ltd	吸収性良好な製剤
CA1188987A (en)	1981-03-06	1985-06-18	Masataka Morishita	Preparation having excellent absorption property
IE54269B1 (en) *	1981-12-30	1989-08-02	Ici America Inc	Pharmaceutically active phenylcarboxylic acid derivatives
US4654327A (en) *	1982-04-21	1987-03-31	Research Corp.	Quaternary ammonium complexes of heparin
US4393192A (en) *	1982-12-21	1983-07-12	The Standard Oil Company	Crystalline copolymers prepared from N,N'-terephthaloyldi-beta-alanine and a glycol
DE3331009A1 (de) *	1983-08-27	1985-03-14	Basf Ag, 6700 Ludwigshafen	Verfahren zur erhoehung der enteralen resorbierbarkeit von heparin bzw. heparinoiden sowie das so erhaeltliche heparin- bzw. heparinoidpraeparat
US4692433A (en) *	1983-10-12	1987-09-08	The Regents Of The University Of California	Method and composition for regulating serum calcium levels of mammals
US4898729A (en) *	1983-12-09	1990-02-06	Euroceltique, S.A.	Treatment of hypertension, compounds and compositions for antihypertension and diuresis
US4757066A (en) *	1984-10-15	1988-07-12	Sankyo Company Limited	Composition containing a penem or carbapenem antibiotic and the use of the same
CA1234561A (en)	1985-06-26	1988-03-29	Kenneth M. White	Profiled body roller-reamer stabilizer
IL77186A0 (en)	1985-11-29	1986-04-29	Touitou Elka	Pharmaceutical insulin composition
US4689182A (en)	1985-12-20	1987-08-25	Warner-Lambert Company	Benzoic acid and benzoic acid ester derivatives having anti-inflammatory and analgesic activity
LU86258A1 (fr) *	1986-01-21	1987-09-03	Rech Dermatologiques C I R D S	Composes benzamido aromatique,leur procede de preparation et leur utilisation en medecine humaine ou veterinaire et en cosmetique
USRE35862E (en) *	1986-08-18	1998-07-28	Emisphere Technologies, Inc.	Delivery systems for pharmacological agents encapsulated with proteinoids
GB8705477D0 (en)	1987-03-09	1987-04-15	Carlton Med Prod	Drug delivery systems
JPH0725725B2 (ja) *	1987-07-23	1995-03-22	保土谷化学工業株式会社	ベンズアミド誘導体
FR2636238B1 (fr) *	1988-09-14	1994-01-21	Morelle Jean	Nouvelles compositions antisudorales
GB8823731D0 (en)	1988-10-10	1988-11-16	Smith Kline French Lab	Biologically active compounds
FR2639395B1 (fr)	1988-11-18	1991-02-15	Rockwell Cim	Dispositif d'accouplement entre une vitre et un mecanisme de leve-vitre a bras oscillants dans un vehicule automobile
JPH02239980A (ja)	1989-03-15	1990-09-21	Fuji Photo Film Co Ltd	感熱記録材料
GB9007052D0 (en) *	1990-03-29	1990-05-30	Skua Investments Ltd	Pharmaceutical formulations
US6099856A (en) *	1992-06-15	2000-08-08	Emisphere Technologies, Inc.	Active agent transport systems
US5541155A (en) *	1994-04-22	1996-07-30	Emisphere Technologies, Inc.	Acids and acid salts and their use in delivery systems
US5629020A (en) *	1994-04-22	1997-05-13	Emisphere Technologies, Inc.	Modified amino acids for drug delivery
US5447728A (en) *	1992-06-15	1995-09-05	Emisphere Technologies, Inc.	Desferrioxamine oral delivery system
US5451410A (en) *	1993-04-22	1995-09-19	Emisphere Technologies, Inc.	Modified amino acids for encapsulating active agents
US5714167A (en) *	1992-06-15	1998-02-03	Emisphere Technologies, Inc.	Active agent transport systems
US6221367B1 (en) *	1992-06-15	2001-04-24	Emisphere Technologies, Inc.	Active agent transport systems
AU653026B2 (en)	1991-06-07	1994-09-15	Teikoku Seiyaku Kabushiki Kaisha	Physiologically active polypeptide-containing pharmaceutical composition
US5352461A (en) *	1992-03-11	1994-10-04	Pharmaceutical Discovery Corporation	Self assembling diketopiperazine drug delivery system
US5811127A (en) *	1992-06-15	1998-09-22	Emisphere Technologies, Inc.	Desferrioxamine oral delivery system
US5792451A (en) *	1994-03-02	1998-08-11	Emisphere Technologies, Inc.	Oral drug delivery compositions and methods
HU211995B (en) *	1992-06-30	1996-01-29	Gyogyszerkutato Intezet	Process to prepare novel benzoyl amino acid derivs. and pharmaceutical compns. contg.them
US5958457A (en) *	1993-04-22	1999-09-28	Emisphere Technologies, Inc.	Compositions for the delivery of antigens
US5709861A (en) *	1993-04-22	1998-01-20	Emisphere Technologies, Inc.	Compositions for the delivery of antigens
US5643957A (en) *	1993-04-22	1997-07-01	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
AU6819294A (en) *	1993-04-22	1994-11-08	Emisphere Technologies, Inc.	Oral drug delivery compositions and methods
US6001347A (en) *	1995-03-31	1999-12-14	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US5866536A (en) *	1995-03-31	1999-02-02	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US5989539A (en) *	1995-03-31	1999-11-23	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US6090958A (en) *	1995-03-31	2000-07-18	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
CN1151836C (zh) *	1995-03-31	2004-06-02	艾米斯菲尔技术有限公司	用作传送活性剂的化合物和组合物
US5965121A (en) *	1995-03-31	1999-10-12	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US5650386A (en) *	1995-03-31	1997-07-22	Emisphere Technologies, Inc.	Compositions for oral delivery of active agents
US6051258A (en)	1995-06-07	2000-04-18	Emisphere Technologies, Inc.	Proteinoid emulsions and methods for preparation and use thereof
US5750147A (en) *	1995-06-07	1998-05-12	Emisphere Technologies, Inc.	Method of solubilizing and encapsulating itraconazole
IL126318A (en) *	1996-03-29	2004-09-27	Emisphere Tech Inc	Compounds and compositions for delivering active agents and some novel carrier compounds
GB2314189B (en)	1996-06-14	2000-08-09	Mars Inc	Coin handling apparatus
US5990166A (en) *	1997-02-07	1999-11-23	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US5773647A (en) *	1997-02-07	1998-06-30	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US5876710A (en) *	1997-02-07	1999-03-02	Emisphere Technologies Inc.	Compounds and compositions for delivering active agents
US5804688A (en) *	1997-02-07	1998-09-08	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US6051561A (en) *	1997-02-07	2000-04-18	Emisphere Technologies Inc.	Compounds and compositions for delivering active agents
ATE383169T1 (de) *	1997-02-07	2008-01-15	Emisphere Tech Inc	Komponente und zusammensetzungen zur verabreichung von wirkstoffen
US5939381A (en) *	1997-02-07	1999-08-17	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US5879681A (en) *	1997-02-07	1999-03-09	Emisphere Technolgies Inc.	Compounds and compositions for delivering active agents
US5776888A (en) *	1997-02-07	1998-07-07	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US6313088B1 (en) *	1997-02-07	2001-11-06	Emisphere Technologies, Inc.	8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents
US6060513A (en) *	1997-02-07	2000-05-09	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US5863944A (en) *	1997-04-30	1999-01-26	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
AR017426A1 (es) *	1997-12-08	2001-09-05	Smithkline Beecham Corp	Sal de monoargininilo del acido (e)-3-[1-n-butil-5-[2-(2-carboxifenil)metoxi-4-clorofenil]-1h-pirazol-4-il]-2-[(5-metoxi-2,3-dihidrobenzofuran-6-il)metil]-prop-2-enoico, composicion farmaceutica que la contiene, su uso para la manufactura de un medicamento y procedimiento para su preparacion
JP5144861B2 (ja)	1998-07-27	2013-02-13	エミスフェアー・テクノロジーズ・インク	活性剤のデリバリーのための化合物及び組成物
IL140930A0 (en)	1998-08-07	2002-02-10	Emisphere Tech Inc	Compounds and compositions for delivering active agents
US6066015A (en)	1998-08-17	2000-05-23	Brown; James D.	Method and system for anchoring a buoy via a screw-type anchor
WO2000048589A1 (en)	1999-02-22	2000-08-24	Emisphere Holdings, Inc.	Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
ES2235854T3 (es) *	1999-04-05	2005-07-16	Emisphere Technologies, Inc.	Sales disodicas, monohidratos y solvatos etanolicos para aportar agentes activos.
US7049283B2 (en)	2000-12-06	2006-05-23	Novartis Ag	Pharmaceutical compositions for the oral delivery of pharmacologically active agents
CA2620616C (en)	2005-08-25	2016-06-14	Arizona Board Of Regents On Behalf Of The University Of Arizona	Stem cell fusion model of carcinogenesis
US20070048725A1 (en)	2005-08-25	2007-03-01	Arrington Ben O'mar	Machine perfusion of tissue grafts for transplantation
WO2011048589A2 (en)	2009-10-23	2011-04-28	Ben Gurion University Of The Negev Research And Development Authority	Ion exchangers and methods of use thereof

2000
- 2000-04-05 ES ES00921909T patent/ES2235854T3/es not_active Expired - Lifetime
- 2000-04-05 EP EP00921909A patent/EP1175390B1/de not_active Expired - Lifetime
- 2000-04-05 IL IL14554600A patent/IL145546A0/xx active IP Right Grant
- 2000-04-05 JP JP2000609376A patent/JP4588221B2/ja not_active Expired - Lifetime
- 2000-04-05 AU AU42167/00A patent/AU4216700A/en not_active Abandoned
- 2000-04-05 AT AT00921909T patent/ATE288415T1/de active
- 2000-04-05 WO PCT/US2000/009390 patent/WO2000059863A1/en not_active Ceased
- 2000-04-05 CA CA2369591A patent/CA2369591C/en not_active Expired - Lifetime
- 2000-04-05 NZ NZ534409A patent/NZ534409A/xx not_active IP Right Cessation
- 2000-04-05 DE DE60017888T patent/DE60017888T2/de not_active Expired - Lifetime
2001
- 2001-09-21 IL IL145546A patent/IL145546A/en not_active IP Right Cessation
- 2001-09-24 US US09/962,794 patent/US20020065255A1/en not_active Abandoned
2003
- 2003-07-07 US US10/615,213 patent/US7384982B2/en not_active Expired - Lifetime
2004
- 2004-11-09 JP JP2004325632A patent/JP4642435B2/ja not_active Expired - Lifetime
2005
- 2005-01-05 IL IL166158A patent/IL166158A/en not_active IP Right Cessation
2006
- 2006-12-17 IL IL180118A patent/IL180118A/en not_active IP Right Cessation
2008
- 2008-04-29 US US12/111,750 patent/US7659311B2/en not_active Expired - Fee Related
2009
- 2009-12-18 US US12/642,508 patent/US8003697B2/en not_active Expired - Fee Related
2011
- 2011-03-22 US US13/053,641 patent/US8207227B2/en not_active Expired - Fee Related
2012
- 2012-05-25 US US13/481,310 patent/US8658695B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US20080269134A1 (en)	2008-10-30
DE60017888D1 (de)	2005-03-10
IL180118A (en)	2010-12-30
US20040106825A1 (en)	2004-06-03
ES2235854T3 (es)	2005-07-16
JP4588221B2 (ja)	2010-11-24
EP1175390A1 (de)	2002-01-30
IL166158A0 (en)	2006-01-15
US20100099621A1 (en)	2010-04-22
CA2369591C (en)	2011-06-14
DE60017888T2 (de)	2006-01-19
US8207227B2 (en)	2012-06-26
JP2002541132A (ja)	2002-12-03
US20020065255A1 (en)	2002-05-30
NZ534409A (en)	2006-03-31
US8658695B2 (en)	2014-02-25
JP4642435B2 (ja)	2011-03-02
EP1175390A4 (de)	2002-09-04
CA2369591A1 (en)	2000-10-12
IL166158A (en)	2010-12-30
US7384982B2 (en)	2008-06-10
IL145546A0 (en)	2002-06-30
US20120264834A1 (en)	2012-10-18
US8003697B2 (en)	2011-08-23
JP2005068161A (ja)	2005-03-17
EP1175390B1 (de)	2005-02-02
AU4216700A (en)	2000-10-23
IL180118A0 (en)	2007-06-03
HK1045680A1 (en)	2002-12-06
WO2000059863A1 (en)	2000-10-12
US20110251125A1 (en)	2011-10-13
IL145546A (en)	2007-10-31
US7659311B2 (en)	2010-02-09

Legal Events

Date

Code

Title

Description

2005-11-15

UEP

Publication of translation of european patent specification

Ref document number: 1175390

Country of ref document: EP

Publication	Publication Date	Title
ATE288415T1 (de)	2005-02-15	Dinatrium-salze, monohydrate und ethanol-solvate
BR0008405A (pt)	2002-04-30	Composição de fator viii formulada sem a adição de albumina, uso de uma composição de fator viii, e, método de liofilizar uma formulação farmacêutica aquosa
ES2436152T3 (es)	2013-12-27	Uso de calcitonina en osteoartritis
TR200201874T2 (tr)	2002-10-21	Proteaz inhibitörleri olarak yeni bileşikler ve bileşimler.
DE60031999D1 (de)	2007-01-04	Stabilisierte flüssige pharmazeutische zusammensetzung enthaltend polypeptide
BR9714434A (pt)	2000-05-02	Formulações de interferon liquidas estáveis
BR9510168A (pt)	1997-10-14	Composto poliaminoácido composição forma unitária de dosagem e método par epreparar uma composição
HUP0300684A2 (hu)	2003-09-29	Szomatosztatin analógok, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
NZ593190A (en)	2013-01-25	Factor viii formulations
RU2013150659A (ru)	2015-05-20	Пероральное введение кальцитонина
JP2004521123A5 (de)	2005-12-22
CY1107990T1 (el)	2013-09-04	Τριπεπτιδια και παραγωγα τριπεπτιδιων για τη θepαπεια νευροεκφυλιστικων ασθενειων
AR013157A1 (es)	2000-12-13	Composicion farmaceutica que incluye un analogo nucleotido y proceso para su preparacion
RU2008123380A (ru)	2009-12-27	Фармацевтическая композиция
JP2009515993A5 (de)	2011-11-24
NO955067D0 (no)	1995-12-14	FVII/TF peptider
TW200744993A (en)	2007-12-16	Crystalline forms of the di-sodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid
MY129537A (en)	2007-04-30	Amino acid ester containing azole antifungals
RU2004126145A (ru)	2005-06-27	N-{[(2s)-4-(3,4-дифторбензил)морфолин-2ил]-метил}-2-{3- [(метилсульфонил)амино]фени л}ацетамид в качестве антагониста ccr-3 для лечения восполительных состояний
UY26365A1 (es)	2001-09-28	Sales de disodio, monohidratos, solvatos de etanol para la liberación de agentes activos
PT1363656E (pt)	2005-03-31	Tripeptideos e derivados de tripeptideos para o tratamento de doencas pos-lesionais do sistema nervoso
AR036219A1 (es)	2004-08-25	Sales de disodio, monohidratos, solvatos de etanol para la liberacion de agentes activos
TH51556A (th)	2002-06-24	เกลือไดโซเดียม โมโนไฮเดรต และ เอธานอลซอลเวต สำหรับการส่งมอบตัวกระทำที่ว่องไว
CY1106169T1 (el)	2011-06-08	Συνθεση αποτελουμενη απο προπιονυλ l-καρνιτινη και γλυκινη για την προληψη και/ή θepαπεια των κυτοτοξικων αποτελεσματων που διεγειρονται απο τη χρηση ανοσοκατασταλτικων παραγοντων
TH27915B (th)	1998-02-16	การปรับปรุงความสามารถที่จะทนทานได้ของกรด(สูตร)- อะมิโนที่ออกฤทธิ์ทางเภสัชกรรม